Session » Systemic Sclerosis & Related Disorders – Basic Science Poster II

Date: Monday, November 18, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 1817

Activated Macrophages Mediate Loss of Dermal White Adipose Tissue in Fibrotic Skin

10:30AM-12:30PM: Abstract Number: 1834

Altered Mechanotransduction via Myosin II Contributes to Collagen and IL-6 Production in Systemic Sclerosis Skin

10:30AM-12:30PM: Abstract Number: 1822

Analysis of Differential Activation of Lysophosphatidic Acid Regulated Genes in Diffuse and Limited Cutaneous Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 1827

Characterization of Fibroblast Subpopulations and Their Cellular Local Environments in Systemic Sclerosis Using Imaging Mass Cytometry

10:30AM-12:30PM: Abstract Number: 1820

Disruption of Ca2+ Homeostasis and Enhanced Ca2+ Signaling in Scleroderma Fibroblasts Is Due to the Vicious Cycle Formed by Mitochondrial-derived Reactive Oxygen Species, CaMKII, and ER Extrusion Pump RYR2

10:30AM-12:30PM: Abstract Number: 1818

Distribution and Morphological Changes of Adventitial Fibroblasts in Healthy and Scleroderma Skin

10:30AM-12:30PM: Abstract Number: 1829

Genomic Analysis of Skin Biopsies Differentiates Major Anti-Nuclear Autoantibody Subsets in Limited Cutaneous Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 1823

Identification and Prediction of Systemic Sclerosis Intrinsic Subtypes Using Semi-Supervised and Supervised Learning on Gene Expression Data of Multiple Cohorts

10:30AM-12:30PM: Abstract Number: 1833

Immune Complexes of Antibodies Directed to Angiotensin Receptor type-1 and Extracellular Vesicles Are Unique Modulators Contributing to Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 1819

Insulin-like Growth Factor Binding Protein-7 (IGFBP7) Plays a Pathogenic Role in Dermal Fibrosis and Is Increased in Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 1815

Leveraging Novel Systemic Sclerosis Disease Signatures to Build a Humanized Drug Discovery Funnel

10:30AM-12:30PM: Abstract Number: 1816

Paracrine WNT Signaling Drives Pro-fibrotic Metabolic Activation of Systemic Sclerosis Macrophages

10:30AM-12:30PM: Abstract Number: 1825

Proteomic and Transcriptomic Analysis Reveal Elevated Senescent Signature in Systemic Sclerosis Fibrosis

10:30AM-12:30PM: Abstract Number: 1831

Role of Long Non-Coding RNA H19 in Mediating Skin Fibrosis in Systemic Sclerosis

10:30AM-12:30PM: Abstract Number: 1830

Single-cell RNA Sequencing Profiling of Very Early-Stage Systemic Sclerosis Skin Reveals a Fibroblast Pro-inflammatory Gene Signature and Keratinocyte Dysregulation

10:30AM-12:30PM: Abstract Number: 1821

Single-Cell RNA SequencingBioinformatic Pipeline Optimized for Non-Coding GenesIdentified LINC01503 and MIR193-BHG as Potential Pathogenic Effectors in Systemic Sclerosis Fibroblasts

10:30AM-12:30PM: Abstract Number: 1824

Skin Macrophage Subtypes and Impact of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis: Results from Single-cell Analyses of an Observational Data Set and a Phase I/II Randomized Controlled Trial

10:30AM-12:30PM: Abstract Number: 1828

SSc Fibroblasts Trigger a Systemic Type I Interferon Response in SSc Patients Through Canonical TGF-β Receptor Signalling

10:30AM-12:30PM: Abstract Number: 1832

Targeting Hippo Pathway Diminishes Disease Signaling in Scleroderma Skin

10:30AM-12:30PM: Abstract Number: 1814

Understanding Monocyte Derived Macrophages in the Skin of SSc Patients Through Single Cell Analysis of Blister Fluid Immune Cell Populations

10:30AM-12:30PM: Abstract Number: 1826

Unveiling the Primary Cilia Signature Driving Systemic Sclerosis Pathogenesis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].